January 2003
Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  
Dec   Feb


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
PULSE Home Page
EXECUTIVE EDITION

US News
Canada News
UK News
New Zealand News

Consumer Advocacy
Health Care Systems
Managed Care/Medicaid
Co-occurring Disorders
Clinical studies
Pharmaceutical News
Criminal Justice Systems
Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels

Archives

Adding comments

Using the # link

Items that require registration

PULSE syndication

Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland
.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Monday, January 06, 2003


Potential new treatment for people with manic depression
Press release from Shire health International - "AstraZeneca has announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for quetiapine (Seroquel) to be granted a licence for the treatment of acute mania associated with bipolar disorder (manic-depressive illness). The application to the FDA follows the completion of a comprehensive clinical trial programme in bipolar disorder undertaken by AstraZeneca."  
permalink